CLVS - Clovis Oncology, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
32.38
-0.10 (-0.31%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close32.48
Open32.32
Bid31.90 x 1100
Ask32.38 x 800
Day's Range31.45 - 32.58
52 Week Range31.19 - 86.26
Volume688,800
Avg. Volume908,312
Market Cap1.705B
Beta0.97
PE Ratio (TTM)N/A
EPS (TTM)-5.78
Earnings DateOct 30, 2018 - Nov 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est69.17
Trade prices are not sourced from all markets
  • Associated Press3 days ago

    Biopharmaceutical company fined for misleading investors

    BOULDER, Colo. (AP) — A Colorado-based biopharmaceutical company has been penalized more than $20 million for misleading investors about the efficacy of a lung cancer drug under development before raising $300 million in a public stock offering.

  • Boulder biopharma firm, CEO and former exec settle with SEC for $20.8 million
    American City Business Journals3 days ago

    Boulder biopharma firm, CEO and former exec settle with SEC for $20.8 million

    The SEC had alleged the firm misled its investors about the effectiveness of the company’s cancer drug.

  • MarketWatch4 days ago

    SEC fines Clovis Oncology Inc., executives $20.8 million for lying about cancer drug effectiveness

    Clovis Oncology Inc., will pay $20 million to settle charges by the Securities and Exchange Commission that it misled investors about the effectiveness of the company's developmental lung cancer drug, rociletinib, or Roci, according to an SEC press release. Its CEO Patrick Mahaffy, and Erle Mast, the company's former CFO, also settled charges. Over a four-month period starting in July 2015, the company and Mahaffy used its investor presentations, press releases, and SEC filings to inaccurately state that the drug was effective 60% of the time, meaning that in 60% of patients Roci caused targeted tumors to shrink, despite knowing actual results were much lower. Clovis raised approximately $298 million in a public stock offering in July 2015, but its stock price dropped by 70% in November 2015 after disclosing the true effectiveness rate, 28%. The company stopped development of the drug in May 2016. The defendants did not admit or deny the allegations. Mahaffy agreed to a $250,000 penalty and Mast agreed to pay a $100,000 penalty and to pay back $454,145, in proceeds from selling Clovis stock during the relevant period at the inflated prices.

  • Reuters4 days ago

    Clovis Oncology, execs to pay $20 million to settle SEC charges

    U.S. biotechnology company Clovis Oncology Inc and its Chief Executive Patrick Mahaffy and former CFO Erle Mast, will pay more than $20 million to settle charges of misleading investors about the efficacy of a cancer drug, the top U.S. securities regulator said on Tuesday. According to the SEC, Clovis continually told investors that its drug, Roci, caused targeted tumors to shrink in 60 percent of patients, when data showed it had actually caused tumor shrinkage in 42 percent of patients. Once Clovis disclosed the true efficacy rate at the end of 2015, its stock price dropped about 70 percent, the SEC added.

  • See what the IHS Markit Score report has to say about Clovis Oncology Inc.
    Markit9 days ago

    See what the IHS Markit Score report has to say about Clovis Oncology Inc.

    Short interest is moderately high for CLVS with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.

  • Business Wire16 days ago

    Clovis Oncology to Present at the Morgan Stanley Global Healthcare Conference

    Clovis Oncology, Inc. (CLVS) today announced that Patrick J. Mahaffy, Chief Executive Officer and President, will present at the 16th Annual Morgan Stanley Global Healthcare Conference on Thursday, September 13, 2018 at 2:55 PM Eastern Time. The conference will be held at the Grand Hyatt New York in New York City. A live webcast of the presentation can be accessed through the investor relations section of the Company’s website at www.clovisoncology.com.

  • Investor's Business Daily17 days ago

    This Biotech Got A Bullish Pop On Its Experimental Cancer Regimen

    Tesaro stock popped in bullish fashion Wednesday after the biotech reported an experimental regimen was successful in 64% of lung cancer patients tested.

  • Why Is Clovis (CLVS) Down 12.9% Since Last Earnings Report?
    Zacks22 days ago

    Why Is Clovis (CLVS) Down 12.9% Since Last Earnings Report?

    Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • A Look at Portola Pharmaceuticals’ Financial Position
    Market Realist25 days ago

    A Look at Portola Pharmaceuticals’ Financial Position

    Portola Pharmaceuticals (PTLA) reported net revenues of $4.0 million in the second quarter. PTLA posted net revenues of $3.8 million in the second quarter of 2017, reflecting ~6.0% YoY (year-over-year) growth. In the first half, Portola Pharmaceuticals reported net revenues of $10.7 million, compared to $8.9 billion in the first half of 2017.

  • Why Analysts Are Positive on Portola Pharmaceuticals in August
    Market Realist25 days ago

    Why Analysts Are Positive on Portola Pharmaceuticals in August

    Portola Pharmaceuticals (PTLA) stock closed at $28.74 on August 27, which represents ~2.02% growth from its close of $28.17 on August 24. On August 24, Portola Pharmaceuticals stock witnessed ~9.06% growth to reach $28.17 from its August 23 close of $25.83.

  • GlobeNewswire26 days ago

    Recent Analysis Shows KalVista Pharmaceuticals, IZEA, Sonic Automotive, Catabasis Pharmaceuticals, ANI Pharmaceuticals, and Clovis Oncology Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Aug. 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of KalVista ...

  • What Does Clovis Oncology’s Valuation Trend Indicate?
    Market Realist29 days ago

    What Does Clovis Oncology’s Valuation Trend Indicate?

    The share price of Clovis Oncology (CLVS) has been on a downward trajectory so far in 2018. From its level of $67.72 on January 4, which has been the high point for it in 2018, Clovis stock has fallen to its current level of $36 in August.

  • Clovis’s Rubraca Keeps Investors Interested
    Market Realist29 days ago

    Clovis’s Rubraca Keeps Investors Interested

    Clovis Oncology (CLVS) is a biopharmaceutical company engaged in the development and marketing of anticancer agents. Clovis’s Rubraca has been approved for the treatment of epithelial ovarian, fallopian tube, and primary peritoneal cancer.

  • Analyzing Clovis Oncology’s Financial Performance
    Market Realist29 days ago

    Analyzing Clovis Oncology’s Financial Performance

    Clovis Oncology (CLVS) generated product revenue from its sales of Rubraca of $23.76 million in the second quarter compared to $14.62 million in the second quarter of 2017. Clovis Oncology incurred a product cost of sales of $4.49 million in the second quarter compared to $2.73 million in the second quarter of 2017. Clovis expects its SG&A expenses to increase due to its support activities for the commercialization of Rubraca in the United States and Europe.

  • See what the IHS Markit Score report has to say about Clovis Oncology Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Clovis Oncology Inc.

    Short interest is moderately high for CLVS with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.

  • Exact Sciences: Why the Stock Price Is Soaring
    Market Realistlast month

    Exact Sciences: Why the Stock Price Is Soaring

    On August 22, Exact Sciences (EXAS) is trading at a stock price of $62.95, which represents ~25.78% growth from the close of $50.05 on August 21.

  • Here’s What Tesaro’s Valuation Trend Indicates
    Market Realistlast month

    Here’s What Tesaro’s Valuation Trend Indicates

    Tesaro’s (TSRO) Phase 3 PRIMA trial of Zejula to evaluate it for the treatment of women with newly diagnosed ovarian cancer, irrespective of BRCA mutation status, has been completely enrolled. Its Phase 2 trial of Zejula in combination with an anti-PD-1 antibody in first-line non-small cell lung cancer is ongoing. The company expects to present data in the first half of 2019. In its immuno-oncology pipeline, Tesaro plans to submit a BLA (Biologic License Application) for TSR-042 in 2019.

  • Analysts’ Expectations for Tesaro and Its Peers in August
    Market Realistlast month

    Analysts’ Expectations for Tesaro and Its Peers in August

    Tesaro (TSRO) is a commercial-stage biopharmaceutical company primarily focused on developing treatments for solid tumors by using small molecules and immune-oncology antibodies both as monotherapies and in combinations. Tesaro’s key product, Zejula, has been approved in the United States as well as the European Union as a maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Tesaro commercialized Zejula in the United States in April 2017 and in Europe in December 2017.

  • Puma Biotechnology: Recent Developments and Recommendations
    Market Realistlast month

    Puma Biotechnology: Recent Developments and Recommendations

    In June, the Committee for Medicinal Products for Human Use recommended a favorable opinion on the approval of Puma Biotechnology’s (PBYI) Nerlynx for its commercialization in the European Union for the prolonged adjuvant therapy of adults with early-stage HER2+ (hormone-receptor-positive) breast cancer whose prior adjuvant trastuzumab-based therapy is less than one year from completion.

  • How Puma Biotechnology Performed in Q2 2018
    Market Realistlast month

    How Puma Biotechnology Performed in Q2 2018

    Puma Biotechnology (PBYI) released its second-quarter earnings results on August 9. It reported net revenue of $117.3 million in the first half of 2018. Puma Biotechnology’s revenue came primarily from its sales of Nerlynx.

  • Here’s How Exelixis Is Financially Positioned Now
    Market Realistlast month

    Here’s How Exelixis Is Financially Positioned Now

    Exelixis (EXEL) generated net revenues of $186.1 million in the second quarter of 2018 compared to $99 million in the second quarter of 2017. In the first half of 2018, Exelixis reported revenues of $399.8 million compared to $179.9 million in the first half of 2017. In the first half of 2018, Exelixis generated revenues of $280.1 million, reflecting ~92% YoY (year-over-year) growth.

  • Analyst Recommendations for Exelixis in August
    Market Realistlast month

    Analyst Recommendations for Exelixis in August

    In the second quarter, Exelixis’s (EXEL) cabozantinib franchise generated revenues of $145.8 million, which was a ~66% YoY (year-over-year) growth. Exelixis’s net product revenues grew 9% sequentially in the second quarter. In the second quarter, Ipsen, Exelixis’s partner, generated cumulative revenues of $150 million from sales of cabozantinib.

  • See what the IHS Markit Score report has to say about Clovis Oncology Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Clovis Oncology Inc.

    Short interest is moderately high for CLVS with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ETFs that hold CLVS had net inflows of $279 million over the last one-month.

  • Business Wirelast month

    Clovis Oncology Announces First Patient Enrolled in the Phase 3 ATHENA Trial

    Trial to Evaluate the Combination of Rubraca® and OPDIVO® in Patients with Advanced Ovarian Cancer

  • Investor's Business Daily2 months ago

    Tesaro CEO Says Its Drug 'Will Get There' — Analysts Strongly Disagree

    Tesaro stock crashed to a four-year low Friday after the biotech cut its 2018 outlook and analysts suggested its key drug, Zejula, is struggling to gain traction in the U.S.